HEALTHCARE
Global Active Pharmaceutical Ingredient Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Active Pharmaceutical Ingredient Market, By Molecule (Small Molecule and Large Molecule), Type (Innovative Active Pharmaceutical Ingredients and Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer and Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, and Others), Drug Type (Prescription Drugs and Over-the-Counter), Usage (Clinical and Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients and Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS and Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology Ophthalmology, and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
Market Dynamics
- Increasing chronic diseases
- Technological advancements in API manufacturing
- Cost and investment in manufacturing
- Regulatory compliance
- Increasing demand for biopharmaceuticals
- Specialty and high-potency APIs
- Ensuring consistent quality and purity
- Patent expirations and pricing pressures
SEGMENTATION
- Molecule
- Small Molecule
- Large Molecule
- Type
- Innovative Active Pharmaceutical Ingredients
- Generic Innovative Active Pharmaceutical Ingredients
- Type of Manufacturer
- Captive API Manufacturer
- Merchant API Manufacturer
- Synthesis
- Synthetic Active Pharmaceutical Ingredients
- Biotech Active Pharmaceutical Ingredients
- Chemical Synthesis
- Acetaminophen
- Artemisinin
- Saxagliptin
- Sodium Chloride
- Ibuprofen
- Losartan Potassium
- Enoxaparin Sodium
- Rufinamide
- Naproxen
- Tamoxifen
- Others
- Drug Type
- Prescription Drugs
- Over-the-Counter
- Usage
- Clinical
- Research
- Potency
- Low-to-Moderate Potency Active Pharmaceutical Ingredients
- Potent-to-Highly Potent Active Pharmaceutical Ingredient
- Therapeutic Application
- Cardiology
- CNS and Neurology
- Oncology
- Orthopedic
- Endocrinology
- Pulmonology
- Gastroenterology
- Nephrology Ophthalmology
- Others
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Novartis AG
- Sanofi
- Pfizer Inc.
- Johnson & Johnson Private Limited
- Abbott
- Bausch Health Companies Inc.
- Sunovion Pharmaceuticals Inc.
- Jazz Pharmaceuticals, Inc.
- AstraZeneca
- GSK plc
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Active Pharmaceutical Ingredient Market, by Molecule
- 3.2 Global Active Pharmaceutical Ingredient Market, by Type
- 3.3 Global Active Pharmaceutical Ingredient Market, by Type of Manufacturer
- 3.4 Global Active Pharmaceutical Ingredient Market, by Synthesis
- 3.5 Global Active Pharmaceutical Ingredient Market, by Chemical Synthesis
- 3.6 Global Active Pharmaceutical Ingredient Market, by Drug Type
- 3.7 Global Active Pharmaceutical Ingredient Market, by Usage
- 3.8 Global Active Pharmaceutical Ingredient Market, by Potency
- 3.9 Global Active Pharmaceutical Ingredient Market, by Therapeutic Application
- 3.10 Global Active Pharmaceutical Ingredient Market, by Geography
- 3.11 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Demand for generic APIs
- 5.1.2 Outsourcing and contract manufacturing
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Increasing chronic diseases
- 5.2.2 Technological advancements in API manufacturing
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 Cost and investment in manufacturing
- 5.3.2 Regulatory compliance
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Increasing demand for biopharmaceuticals
- 5.4.2 Specialty and high-potency APIs
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Ensuring consistent quality and purity
- 5.5.2 Patent expirations and pricing pressures
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY MOLECULE
- 6.1 Molecule Summary
- 6.2 Market Attractive Index
- 6.3 Global Active Pharmaceutical Ingredient Market, by Molecule (2019-2032)
- SECTION 7 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE
- 7.1 Type Summary
- 7.2 Market Attractive Index
- 7.3 Global Active Pharmaceutical Ingredient Market, by Type (2019-2032)
- SECTION 8 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF MANUFACTURER
- 8.1 Type of Manufacturer Summary
- 8.2 Market Attractive Index
- 8.3 Global Active Pharmaceutical Ingredient Market, by Type of Manufacturer (2019-2032)
- SECTION 9 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS
- 9.1 Synthesis Summary
- 9.2 Market Attractive Index
- 9.3 Global Active Pharmaceutical Ingredient Market, by Synthesis (2019-2032)
- SECTION 10 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY CHEMICAL SYNTHESIS
- 10.1 Chemical Synthesis Summary
- 10.2 Market Attractive Index
- 10.3 Global Active Pharmaceutical Ingredient Market, by Chemical Synthesis (2019-2032)
- SECTION 11 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY DRUG TYPE
- 11.1 Drug Type Summary
- 11.2 Market Attractive Index
- 11.3 Global Active Pharmaceutical Ingredient Market, by Drug Type (2019-2032)
- SECTION 12 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY USAGE
- 12.1 Usage Summary
- 12.2 Market Attractive Index
- 12.3 Global Active Pharmaceutical Ingredient Market, by Usage (2019-2032)
- SECTION 13 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY
- 13.1 Potency Summary
- 13.2 Market Attractive Index
- 13.3 Global Active Pharmaceutical Ingredient Market, by Potency (2019-2032)
- SECTION 14 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION
- 14.1 Therapeutic Application Summary
- 14.2 Market Attractive Index
- 14.3 Global Active Pharmaceutical Ingredient Market, by Therapeutic Application (2019-2032)
- SECTION 15 - GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY GEOGRAPHY
- 15.1 Regional Summary
- 15.2 Market Attractive Index
- 15.3 Global Active Pharmaceutical Ingredient Market, by Geography (2019-2032)
- SECTION 16 - NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENT MARKET
- 16.1 North America Summary
- 16.2 Market Attractive Index
- 16.3 North America Active Pharmaceutical Ingredient Market, by Molecule (2019-2032)
- 16.4 North America Active Pharmaceutical Ingredient Market, by Type (2019-2032)
- 16.5 North America Active Pharmaceutical Ingredient Market, by Type of Manufacturer (2019-2032)
- 16.6 North America Active Pharmaceutical Ingredient Market, by Synthesis (2019-2032)
- 16.7 North America Active Pharmaceutical Ingredient Market, by Chemical Synthesis (2019-2032)
- 16.8 North America Active Pharmaceutical Ingredient Market, by Drug Type (2019-2032)
- 16.9 North America Active Pharmaceutical Ingredient Market, by Usage (2019-2032)
- 16.10 North America Active Pharmaceutical Ingredient Market, by Potency (2019-2032)
- 16.11 North America Active Pharmaceutical Ingredient Market, by Therapeutic Application (2019-2032)
- 16.12 North America Active Pharmaceutical Ingredient Market, by Country (2019-2032)
- 16.12.1 U.S.
- 16.12.2 Canada
- 16.12.3 Mexico
- 16.12.4 Rest of North America
- SECTION 17 - EUROPE ACTIVE PHARMACEUTICAL INGREDIENT MARKET
- 17.1 Europe Summary
- 17.2 Market Attractive Index
- 17.3 Europe Active Pharmaceutical Ingredient Market, by Molecule (2019-2032)
- 17.4 Europe Active Pharmaceutical Ingredient Market, by Type (2019-2032)
- 17.5 Europe Active Pharmaceutical Ingredient Market, by Type of Manufacturer (2019-2032)
- 17.6 Europe Active Pharmaceutical Ingredient Market, by Synthesis (2019-2032)
- 17.7 Europe Active Pharmaceutical Ingredient Market, by Chemical Synthesis (2019-2032)
- 17.8 Europe Active Pharmaceutical Ingredient Market, by Drug Type (2019-2032)
- 17.9 Europe Active Pharmaceutical Ingredient Market, by Usage (2019-2032)
- 17.10 Europe Active Pharmaceutical Ingredient Market, by Potency (2019-2032)
- 17.11 Europe Active Pharmaceutical Ingredient Market, by Therapeutic Application (2019-2032)
- 17.12 Europe Active Pharmaceutical Ingredient Market, by Country (2019-2032)
- 17.12.1 Germany
- 17.12.2 U.K.
- 17.12.3 France
- 17.12.4 Italy
- 17.12.5 Spain
- 17.12.6 Russia
- 17.12.7 The Netherlands
- 17.12.8 Belgium
- 17.12.9 Turkey
- 17.12.10 Rest of Europe
- SECTION 18 - ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET
- 18.1 Asia-Pacific Summary
- 18.2 Market Attractive Index
- 18.3 Asia-Pacific Active Pharmaceutical Ingredient Market, by Molecule (2019-2032)
- 18.4 Asia-Pacific Active Pharmaceutical Ingredient Market, by Type (2019-2032)
- 18.5 Asia-Pacific Active Pharmaceutical Ingredient Market, by Type of Manufacturer (2019-2032)
- 18.6 Asia-Pacific Active Pharmaceutical Ingredient Market, by Synthesis (2019-2032)
- 18.7 Asia-Pacific Active Pharmaceutical Ingredient Market, by Chemical Synthesis (2019-2032)
- 18.8 Asia-Pacific Active Pharmaceutical Ingredient Market, by Drug Type (2019-2032)
- 18.9 Asia-Pacific Active Pharmaceutical Ingredient Market, by Usage (2019-2032)
- 18.10 Asia-Pacific Active Pharmaceutical Ingredient Market, by Potency (2019-2032)
- 18.11 Asia-Pacific Active Pharmaceutical Ingredient Market, by Therapeutic Application (2019-2032)
- 18.12 Asia-Pacific Active Pharmaceutical Ingredient Market, by Country (2019-2032)
- 18.12.1 China
- 18.12.2 India
- 18.12.3 Japan
- 18.12.4 South Korea
- 18.12.5 Singapore
- 18.12.6 Malaysia
- 18.12.7 Australia
- 18.12.8 Thailand
- 18.12.9 Philippines
- 18.12.10 Rest of Asia-Pacific
- SECTION 19 - SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENT MARKET
- 19.1 South America Summary
- 19.2 Market Attractive Index
- 19.3 South America Active Pharmaceutical Ingredient Market, by Molecule (2019-2032)
- 19.4 South America Active Pharmaceutical Ingredient Market, by Type (2019-2032)
- 19.5 South America Active Pharmaceutical Ingredient Market, by Type of Manufacturer (2019-2032)
- 19.6 South America Active Pharmaceutical Ingredient Market, by Synthesis (2019-2032)
- 19.7 South America Active Pharmaceutical Ingredient Market, by Chemical Synthesis (2019-2032)
- 19.8 South America Active Pharmaceutical Ingredient Market, by Drug Type (2019-2032)
- 19.9 South America Active Pharmaceutical Ingredient Market, by Usage (2019-2032)
- 19.10 South America Active Pharmaceutical Ingredient Market, by Potency (2019-2032)
- 19.11 South America Active Pharmaceutical Ingredient Market, by Therapeutic Application (2019-2032)
- 19.12 South America Active Pharmaceutical Ingredient Market, by Country (2019-2032)
- 19.12.1 Brazil
- 19.12.2 Argentina
- 19.12.3 Chile
- 19.12.4 Colombia
- 19.12.5 Rest of South America
- SECTION 20 - MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENT MARKET
- 20.1 Middle East and Africa Summary
- 20.2 Market Attractive Index
- 20.3 Middle East and Africa Active Pharmaceutical Ingredient Market, by Molecule (2019-2032)
- 20.4 Middle East and Africa Active Pharmaceutical Ingredient Market, by Type (2019-2032)
- 20.5 Middle East and Africa Active Pharmaceutical Ingredient Market, by Type of Manufacturer (2019-2032)
- 20.6 Middle East and Africa Active Pharmaceutical Ingredient Market, by Synthesis (2019-2032)
- 20.7 Middle East and Africa Active Pharmaceutical Ingredient Market, by Chemical Synthesis (2019-2032)
- 20.8 Middle East and Africa Active Pharmaceutical Ingredient Market, by Drug Type (2019-2032)
- 20.9 Middle East and Africa Active Pharmaceutical Ingredient Market, by Usage (2019-2032)
- 20.10 Middle East and Africa Active Pharmaceutical Ingredient Market, by Potency (2019-2032)
- 20.11 Middle East and Africa Active Pharmaceutical Ingredient Market, by Therapeutic Application (2019-2032)
- 20.12 Middle East and Africa Active Pharmaceutical Ingredient Market, by Country (2019-2032)
- 20.12.1 Kingdom of Saudi Arabia
- 20.12.2 South Africa
- 20.12.3 U.A.E.
- 20.12.4 Egypt
- 20.12.5 Rest of Middle East and Africa
- SECTION 21 - COMPANY SHARE ANALYSIS
- 21.1 Global Active Pharmaceutical Ingredient Market, Company Share Analysis
- 21.2 North America Active Pharmaceutical Ingredient Market, Company Share Analysis
- 21.3 Europe Active Pharmaceutical Ingredient Market, Company Share Analysis
- 21.4 Asia-Pacific Active Pharmaceutical Ingredient Market, Company Share Analysis
- SECTION 22 - COMPANY PROFILES
- 22.1 Novartis AG
- 22.1.1 Company Snapshot
- 22.1.2 Financial Overview
- 22.1.3 Product Portfolio
- 22.1.4 Recent Developments
- 22.2 Sanofi
- 22.2.1 Company Snapshot
- 22.2.2 Financial Overview
- 22.2.3 Product Portfolio
- 22.2.4 Recent Developments
- 22.3 Pfizer Inc.
- 22.3.1 Company Snapshot
- 22.3.2 Financial Overview
- 22.3.3 Product Portfolio
- 22.3.4 Recent Developments
- 22.4 Johnson & Johnson Private Limited
- 22.4.1 Company Snapshot
- 22.4.2 Financial Overview
- 22.4.3 Product Portfolio
- 22.4.4 Recent Developments
- 22.5 Abbott
- 22.5.1 Company Snapshot
- 22.5.2 Financial Overview
- 22.5.3 Product Portfolio
- 22.5.4 Recent Developments
- 22.6 Bausch Health Companies Inc.
- 22.6.1 Company Snapshot
- 22.6.2 Financial Overview
- 22.6.3 Product Portfolio
- 22.6.4 Recent Developments
- 22.7 Sunovion Pharmaceuticals Inc.
- 22.7.1 Company Snapshot
- 22.7.2 Financial Overview
- 22.7.3 Product Portfolio
- 22.7.4 Recent Developments
- 22.8 Jazz Pharmaceuticals, Inc.
- 22.8.1 Company Snapshot
- 22.8.2 Financial Overview
- 22.8.3 Product Portfolio
- 22.8.4 Recent Developments
- 22.9 AstraZeneca
- 22.9.1 Company Snapshot
- 22.9.2 Financial Overview
- 22.9.3 Product Portfolio
- 22.9.4 Recent Developments
- 22.10 GSK plc
- 22.10.1 Company Snapshot
- 22.10.2 Financial Overview
- 22.10.3 Product Portfolio
- 22.10.4 Recent Developments
- SECTION 23 - RELATED REPORTS
- SECTION 24 - DISCLAIMER
RESEARCH METHODOLOGY
RESEARCH AND DATA COLLECTION
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.